Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6831509 | 0.98 | RAB9A (0.73) | RAB9AALDH1A1TDP1KDM4EMAPK8 | |
| SCHEMBL6120093 | 0.88 | RAB9A (0.72) | RAB9AALDH1A1TDP1KDM4EMAPK8 | |
| SCHEMBL17241997 | 0.87 | RAB9A (0.76) | RAB9AALDH1A1TDP1KDM4EKMT2A | |
| SCHEMBL861902 | 0.86 | TDP1 (0.71) | RAB9AALDH1A1TDP1KDM4EMAPK8 | |
| SCHEMBL6455377 | 0.86 | RAB9A (0.74) | RAB9AALDH1A1TDP1KDM4EKMT2A | |
| SCHEMBL4165132 | 0.86 | RAB9A (0.74) | RAB9AALDH1A1TDP1KDM4EKMT2A | |
| SCHEMBL28662140 | 0.86 | RAB9A (1.00) | RAB9AALDH1A1TDP1KDM4EROCK2 | |
| SCHEMBL1457550 | 0.85 | ALDH1A1 (0.63) | RAB9AALDH1A1TDP1KDM4EMAPK8 | |
| SCHEMBL20641267 | 0.84 | RAB9A (0.67) | RAB9AALDH1A1ROCK2 | |
| SCHEMBL7312518 | 0.84 | RAB9A (0.59) | RAB9AALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-3743406-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145726-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | WO | disclosed |
| EP-3203840-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| US-9249114-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-20140148457-A1 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010114726-A1 | AMINOBENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-5328845-A | Fungal negative microorganism capable of producing high levels of beta-carotene | UNIVERSAL FOODS CORPORATION (US) | 1994-07-12 | — | — | US | disclosed |
| WO-1994008991-A1 | HERBICIDAL PYRAZOLYLOXY-PICOLINAMIDES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1994-04-28 | — | — | WO | disclosed |
| WO-1993020183-A1 | METHOD FOR PRODUCING BETA-CAROTENE USING A FUNGAL MATED CULTURE | UNIVERSAL FOODS CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0357316-B1 | ANTIDEPRESSANT N-SUBSTITUTED NICOTINAMIDE COMPOUNDS | PFIZER INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| EP-0488474-A1 | Herbicidal carboxamide derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-06-03 | — | — | EP | disclosed |
| EP-0357316-A1 | Antidepressant N-substituted nicotinamide compounds | PFIZER INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4861891-A | Antidepressant N-substituted nicotinamide compounds | PFIZER INC. (US) | 1989-08-29 | — | — | US | disclosed |
| US-4327218-A | HERBICIDES | STAUFFER CHEMICAL COMPANY (US) | 1982-04-27 | — | — | US | disclosed |
| US-4251263-A | N-substituted, 2-phenoxynicotinamide compounds and the herbicidal use thereof | STAUFFER CHEMICAL COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | RAB9A 2748/4885ALDH1A1 1278/4885TDP1 2797/4885 |
| US-20140148457-A1 | Thiazole derivatives | TBK1, IRAK1, IRF3 | RAB9A 1533/4885ALDH1A1 3473/4885TDP1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.